

Immune response of primary and booster immunity of SARS-CoV-2 vaccination among patients with chronic liver disease: a real-world study

Ruixin Song^{1#}, Chao Yang^{2#}, Jiayin Wang^{1#}, Qianqian Li^{2#}, Jing Chen^{1#}, Kai Sun³, Hongmin Lv², Yankai Yang², Jing Liang², Qing Ye², YanYing Gao², Jun Li², Ying Li², Junqing Yan², Ying Liu², Tao Wang², Changen Liu², Fei Wang², Weili Yin², Huiling Xiang^{2*}

1.The Third Central Clinical College of Tianjin Medical University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin Third Central Hospital
2.Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease

3.Tianjin Hongqiao Hospital, Tianjin, China

#: Ruixin Song, Chao Yang, Jiayin Wang, Qianqian Li, Jing Chen share co-first authorship
Financial support

1.Sponsored by Tianjin Health Research Project. (No: TJWJ2022XK029)

2.Funded by Tianjin Key Medical Discipline (Specialty) Construction Project. (No : TJYXZDXK-034A)

Abstract

Aim: The present study discussed the humoral immune response and antibody dynamics after primary and booster immunity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with chronic liver disease (CLD) in the real world. Thus, it provided data to develop SARS-CoV-2 vaccination strategy.

Methods: Patients with confirmed CLD and completed primary or booster immunity of SARS-CoV-2 vaccines were enrolled. Serological specimens were collected after primary or booster immunity of SARS-CoV-2 vaccines to detect novel coronavirus neutralizing antibody (nCoV NTA_b) and novel coronavirus spike receptor-binding domain antibody (nCoV S-RBD). Thus, we could evaluate the humoral immune response and antibody dynamics after primary and booster immunity of SARS-CoV-2 vaccines among patients with CLD. Simultaneously, baseline demographics, liver disease-related situations,

comorbidity-related situations, SARS-CoV-2 vaccination information,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

and laboratory examination-related indicators of patients were collected.

Results: A total of 315 patients received SARS-CoV-2 vaccines, including 223 patients who completed the primary immunity of SARS-CoV-2 vaccines, 114 patients who completed booster immunity of SARS-CoV-2 vaccines, and 22 patients who underwent the antibody detection of SARS-CoV-2 vaccines after both primary and booster immunities. The positive rate of nCoV NTAb was 59.64% in Primary and 87.72% in Booster ($P<0.001$). The median level of nCoV NTAb was 11.53 AU/mL in Primary and 31.98 AU/mL in Booster ($P<0.001$). The positive rate of nCoV S-RBD was 69.06% in Primary and 91.23% in Booster ($P<0.001$). The median level of nCoV S-RBD was 21.60AU/mL in Primary and 112.65 AU/mL in Booster ($P<0.001$). After booster immunity of SARS-CoV-2 vaccines in 22 patients, the positive rate of nCoV NTAb increased from 59.09% to 86.36%, and that of nCoV S-RBD increased from 68.18% to 90.91%. The median level of nCoV NTAb increased from 11.24 AU /mL to 59.14 AU /mL after booster immunity. The median level of nCoV S-RBD increased from 27.28 AU/mL to 219.10 AU/mL. Compared to the antibody level of primary immunity, the median level of nCoV NTAb and nCoV S-RBD in 22 patients was increased by 5.26 and 8.03 times, respectively. Among 22 patients, 9 were negative for nCoV NTAb after primary immunity, while 6 were transformed positive after booster immunity, and the positive conversion rate of nCoV NTAb was 66.7%. On the other hand, 7 patients were negative for nCoV S-RBD after primary immunity, while 5 were transformed positive after booster immunity, and the positive conversion rate of nCoV S-RBD was 71.4%.

Conclusion: Patients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD. Finally, the positive conversion rate among patients with primary immunity failure also can be improved after booster immunity.

Keywords: immune response; primary and booster immunity; SARS-CoV-2 vaccination; chronic liver disease

The global cumulative number of confirmed cases of coronavirus disease 2019 (COVID-19) has reached 620 million, and the cumulative number of deaths reached 6.55 million in October 2022^[1]. In order to prevent the further spread of the virus, the vaccination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been implemented successively worldwide. Among the 20–59-year-old age group, the effectiveness of two doses of BNT162b2 and CoronaVac vaccine preventing severe illness and death after COVID-19 diagnosis was 96.3% and 91.7%, respectively^[2]. Patients with chronic liver disease (CLD) have congenital and adaptive immune cell suppression^[3], a high risk of SARS-CoV-2 infection, and an inclination to develop complications and mortality; hence, these patients should be the focus of SARS-CoV-2 vaccination^[4]. After two doses of SARS-CoV-2 vaccines for patients with CLD, the positive rate of novel coronavirus neutralizing antibody (nCoV NTAbs) and novel coronavirus spike receptor-binding domain antibody (nCoV S-RBD) was 87.8% and 87.8%^[5], respectively. Up to October 2022, 241.15 doses of SARS-CoV-2 vaccines have been administered per 100 individuals, and 89.2% of the population has completed the primary immunity of SARS-CoV-2 vaccines in China^[6]. As a consequence of the decreasing effectiveness of SARS-CoV-2 vaccines^[7, 8], the World Health Organization (WHO) has advocated a booster dose of SARS-CoV-2 vaccine. Compared to the two doses of SARS-CoV-2

vaccines, the effectiveness of three doses in preventing the occurrence of COVID-19 is 95.3%^[9]. Notably, three doses reduce the hospitalization rate, disease severity, and mortality^[10]. Several studies have discussed the humoral immune response of patients with CLD after primary immunity with SARS-CoV-2 vaccines. However, data regarding booster immunity on the humoral immune response in patients with CLD are yet lacking. The present study aimed to discuss the humoral immune response and antibody dynamics after completing the primary and booster immunity of SARS-CoV-2 vaccines among patients with CLD in a real world. Thus, this study provides data support for the development of SARS-CoV-2 vaccination strategy.

1. Study design and methods

1.1 Inclusion and exclusion criteria

Patients visiting the hepatology outpatient clinic of the Third Central Hospital of Tianjin in China between January 2021 and June 2022 were enrolled in this study. The inclusion criteria were as follows: 1. Age ≥ 18 years; 2. CLD diagnosed by clinical data or medical history; 3. Completion of primary immunity or booster immunity of SARS-CoV-2 vaccines; 4. Willingness to comply with research procedures and provide written informed consent.

The exclusion criteria included pregnancy, lactation, active or history of COVID-19 infection, known liver transplantation,

immunosuppressive or immunodeficiency status [including human immunodeficiency virus (HIV) infection], and history of systemic immunosuppressants, systemic immunoglobulins, or immune boosters within 3 months.

1.2 Diagnostic basis of CLD

The definition of CLD is liver disease lasting >6 months, including chronic liver inflammation (hepatitis B virus, hepatitis C virus, alcoholic liver disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and non-alcoholic fatty liver disease), irrespective of cirrhosis. The diagnostic criteria for cirrhosis are based on the Guidelines for Diagnosis and Treatment of Cirrhosis^[11].

1.3 Vaccine types and injection protocol

The types of vaccines in this study included CoronaVac vaccine (Beijing Sinovac Life Sciences Co., Ltd, China), BBIBP-CorV vaccine (Beijing Institute of Biological Products Co., Ltd, China), CanSinoBio Ad5-nCoV vaccine (CanSino Biologics Inc. China), and Zifivax vaccine (CHO cells) (Anhui Zhifei Longcom Biopharmaceutical Co., Ltd, China). The vaccination protocol was based on the Guidelines for SARS-CoV-2 Vaccination^[12]. CoronaVac and BBIBP-CorV vaccines are inactivated and require two doses at an interval of 3–8 weeks, with a booster dose at least 6 months away from the

second dose. CanSinoBio Ad5-nCoV vaccine is an adenovirus vector vaccine that requires one dose; a booster dose is at least 6 months apart from the first dose. The Zifivax vaccine is a recombinant subunit vaccine requiring three doses, 4–8 weeks intervals between each dose, and does not require a booster dose.

1.4 Clinical data collection

Clinical data included baseline demographics [age, gender, race, and body mass index (BMI)], liver disease-related situation (etiology, absence or presence cirrhosis, and Child-Pugh class), comorbidity-related situation (hypertension, diabetes, coronary artery disease, asthma, and arrhythmia), SARS-CoV-2 vaccination information (the type of vaccine and the date of completion primary or booster immunity), laboratory examination-related indicators (alanine aminotransferase, aspartate aminotransferase, albumin, total bilirubin, gamma-glutamyl transpeptidase, and alkaline phosphatase).

1.5 Assessment of immune response

Serological specimens were collected after completion of primary or booster immunity of SARS-CoV-2 vaccines to detect nCoV NTAb and nCoV S-RBD [competitive combination chemiluminescence immunoassay (CLIA) method by Shenzhen Mindray Bio-Medical Electronics Co., Ltd, China]. According to

the manufacturer's instructions, the measurement range is 2.0–400.0 AU/mL and >10 AU/mL indicated an immune response. The antibody level >10.0 AU/mL was regarded as positive, while antibody level <10.0 AU/mL was regarded as negative.

1.6 Safety assessment

Local and systemic adverse reactions of patients with CLD after primary and booster immunity of SARS-CoV-2 vaccines were recorded. The local adverse reactions included pain, swelling, redness, induration, pruritus at the injection site, and their severity. Systemic adverse reactions included fever, dizziness, fatigue, nausea, vomiting, decreased appetite, myalgia, arthralgia, oropharyngeal pain, cough, allergy, dyspnea, syncope, pruritus (non-injection site), and their severity.

1.7 Statistical analysis

If continuous variables conformed to the normal distribution, they were represented by mean±standard deviation. In the case of non-normal distribution, the data were represented by the median and interquartile range (IQR). The categorical variables were expressed by the frequencies and percentages of each type. Continuous variables were assessed by t-test and nonparametric test to evaluate whether the difference between the groups was statistically significant. Categorical variables were evaluated for

statistically significant differences between groups using Pearson's χ^2 test and Fisher's exact test. Using the two-sided test, P-values <0.05 were significant. Statistical software used EmpowerStats (www.empowerstats.com; X&Y Solutions Inc.) and the statistical package R (The R Foundation; <http://www.r-project.org>; version 3.4.3). The images were generated using Origin 2022b.

1.8 Medical ethics

This study was approved by the Ethics Committee of Tianjin Third Central Hospital, China. The ethics approval number was IRB 2021-027-01. All participants signed written informed consent prior to registration.

2. Results

2.1 Baseline demographic and clinical characteristics

A total of 315 patients completed SARS-CoV-2 vaccines and were divided into primary and booster immunity groups according to the status of vaccination. In this study, the primary immunity group was referred to as Primary, and the booster immunity group was referred to as Booster. Primary included 223 patients who completed the primary immunity of SARS-CoV-2 vaccines, and Booster included 114 patients who completed booster immunity of SARS-CoV-2 vaccines. The median age of

the primary and booster groups was 55.0 (IQR: 43.0–63.0) years and 53.0 (IQR: 43.8–60.0) years, respectively, and no significant difference was observed between the two groups ($P=0.331$).

Males accounted for 58.7% and 63.2% in Primary and Booster, respectively, with no difference between the two groups ($P=0.433$). Regarding etiology, CLD was caused by hepatitis B virus, and the proportion of hepatitis B was 68.2% and 86.0%, respectively, with statistical significance between the two groups ($P=0.003$). The median time between primary immunity completion to serological specimen collection was 53 (IQR: 31–100) days, and the median time between booster immunity completion and serological specimen collection was 102 (IQR: 45–145) days, with statistical significance between the two groups ($P<0.001$) (Table 1).

2.2 Immune response assessment

2.2.1 nCoV NTAb

The positive rate of nCoV NTAb was 59.64% in Primary and 87.72% in Booster ($P<0.001$) (Table 2 and Figure 1A). A booster dose increased nCoV NTAb positivity rate by 28.08%. The median level of nCoV NTAb was 11.53 (IQR: 8.09–20.28) AU/mL in Primary and 31.98 (IQR: 15.37–96.02) AU/mL in Booster ($P<0.001$) (Table 2 and Figure 1B). A booster dose

increased the level of nCoV NTAbs by 2.77-fold.

Subgroup analysis: The humoral immune response of non-cirrhosis and cirrhosis was compared in Primary and Booster. After Primary, the positive rate of nCoV NTAbs was 59.3% and 60.0% in non-cirrhosis and cirrhosis patients ($P=0.910$), respectively, and the median level was 11.19 (IQR: 7.85–20.26) AU/mL and 11.98 (IQR: 8.21–20.61) AU/mL in non-cirrhosis and cirrhosis ($P=0.930$), respectively. After Booster, the positive rate of nCoV NTAbs was 93.5% and 80.8% in non-cirrhosis and cirrhosis ($P=0.048$), respectively, and the median level was 31.41 (IQR: 19.49–96.02) AU/mL and 32.65 (IQR: 11.58–99.85) AU/mL in non-cirrhosis and cirrhosis, respectively ($P=0.651$) (Table 3 and Figure 2A).

2.2.2 nCoV S-RBD

The positive rate of nCoV S-RBD was 69.06% in Primary and 91.23% in Booster ($P<0.001$) (Table 2 and Figure 1C). A booster dose increased nCoV S-RBD positivity rate by 22.17%. The median level of nCoV S-RBD was 21.60 (IQR: 7.59–62.95) AU/mL in Primary and 112.65 (IQR: 31.91–286.56) AU/mL in Booster ($P<0.001$) (Table 2 and Figure 1D). A booster dose increased the level of nCoV S-RBD by 5.22 times.

Subgroup analysis: After Primary, the positive rate of nCoV

S-RBD was 66.7% and 71.3% ($P=0.472$), and the median level was 17.58 (IQR: 7.11–49.59) AU/mL and 25.08 (IQR: 8.67–69.09) AU/mL in non-cirrhosis and cirrhosis, respectively ($P=0.217$). After Booster, the positive rate of nCoV S-RBD was 98.4% and 82.7% ($P=0.009$), and the median level was 102.94 (IQR: 50.38–286.91) AU/mL and 119.42 (IQR: 17.44–287.05) AU/mL in non-cirrhosis and cirrhosis, respectively ($P=0.159$) (Table 3 and Figure 2B).

2.2.3 Antibody dynamics after booster immunity

A total of 22 patients underwent antibody detection of SARS-CoV-2 vaccines after both primary and booster immunity to further confirm the dynamic changes in antibodies after booster immunity. Subsequently, the positive rate of nCoV NTAbs increased from 59.09% to 86.36%, and that of nCoV S-RBD increased from 68.18% to 90.91% (Table 4 and Figure 3A). The median level of nCoV NTAbs increased from 11.24 (IQR: 8.59–17.00) AU/mL to 59.14 (IQR: 20.89–128.99) AU/mL after booster immunity. The median level of nCoV S-RBD was increased from 27.28 (IQR: 7.80–56.45) AU/mL to 219.10 (IQR: 63.11–456.05) AU/mL (Table 4 and Figure 3B). Compared to the antibody level of primary immunity, the median level of nCoV NTAbs and nCoV S-RBD was increased by 5.26 and 8.03 times,

respectively. In conclusion, after booster immunity of SARS-CoV-2 vaccine, the positive rate and antibody level in patients with CLD can be further improved based on primary immunity. Among 22 patients, 9 were negative for nCoV NTAbs after primary immunity, while 6 cases were transformed positive after booster immunity, and the positive conversion rate of nCoV NTAbs was 66.7% (Figure 3C). Furthermore, 7 patients were negative for nCoV S-RBD after primary immunity, while 5 were transformed into positive after booster immunity, and the positive conversion rate was 71.4% (Figure 3D). The positive conversion rate among patients with primary immunity failure was also improved after booster immunity, such that patients with primary immunity failure can acquire immunity to COVID-19.

After primary immunity, 9/22 cases were negative for nCoV NTAbs, 7/22 were negative for nCoV S-RBD, and 6/22 patients were negative for both nCoV NTAbs and nCoV S-RBD. After primary immunity, the median age of nCoV NTAbs-negative patients was 57.0 (IQR: 46.5–66.0) years higher than 54.0 (IQR: 49.5–67.5) years in nCoV NTAbs-positive patients, and the proportion of cirrhosis in nCoV NTAbs-negative patients was 88.9%, which was higher than 53.8% in nCoV NTAbs-positive patients (Table 5). After primary immunity, the median age of

nCoV S-RBD-negative patients was 57.0 (IQR: 48.0–74.0) years higher than 54.0 (IQR: 48.0–67.0) years of nCoV S-RBD-positive patients, and the proportion of cirrhosis in nCoV S-RBD-negative patients was 85.7% higher than 60.0% in nCoV S-RBD-positive patients (Table 6).

2.3 Safety assessment

After primary immunity, 51/223 (22.9%) patients reported at least one adverse event. The most common local adverse reaction was pain at the injection site (21, 9.4%), followed by pruritus (2, 0.9%) and swelling (1, 0.4%). The most common systemic adverse reaction was fatigue (16, 7.2%), followed by nausea (6, 2.7%), fever (5, 2.2%), dizziness (5, 2.2%), decreased appetite (5, 2.2%), myalgia (4, 1.8%), arthralgia (2, 0.9%), and cough (2, 0.9%). Most of the local and systemic adverse reactions after primary immunity were mild and resolved over time.

After booster immunity, 29/114 (25.4%) patients reported at least one adverse event. The most common local adverse reaction was pain at the injection site (16, 14.0%), followed by pruritus (1, 0.9%). The most common systemic adverse reaction was fatigue (5, 4.4%), followed by nausea (4, 3.5%), dizziness (3, 2.6%), decreased appetite (2, 1.8%), fever (1, 0.9%), myalgia (1, 0.9%), arthralgia (1, 0.9%), and cough (1, 0.9%). Most of the local and

systemic adverse reactions after booster immunity were mild and self-limiting.

3. Discussion

COVID-19 has become a public health emergency endangering human health; vaccination against SARS-CoV-2 is a major preventive measure. A previous study showed that the effectiveness of the two doses of SARS-CoV-2 vaccines was 95% in preventing COVID-19^[13]. After two doses of SARS-CoV-2 vaccines in healthy people, the positive rate of nCoV S-RBD was 99.6%^[14]. In another study, two doses of SARS-CoV-2 vaccines effectuated a serological conversion of SARS-CoV-2 antibodies up to 100% in healthy individuals^[15].

Patients with comorbidities have a high morbidity of COVID-19 and are prone to develop severe illness and death^[16]. The serological conversion rates of nCoV S-RBD in patients with HIV, hematopoietic stem cell transplantation, primary immunodeficiency diseases, chronic lymphocytic leukemia, and solid organ transplantation were 98.7%, 84.7%, 73.3%, 63.3%, and 43.4%, respectively, while that of the healthy control group was 100.0%^[17]. After two doses of SARS-CoV-2 vaccines, the inhibitory level of nCoV NTAbs in ovarian cancer patients was 83.6%, which was significantly lower than that of the healthy

control group (92.9%)^[18]. In this study, the positive serological rates of nCoV NTAb and nCoV S-RBD were 59.64% and 69.06% in patients with CLD after primary immunity of SARS-CoV-2 vaccine. Compared to a previous study^[19], the positive rate of nCoV NTAb in this study was lower, which might be due to older age [55.0 (IQR: 43.0–63.0) years *vs.* 47.0 (IQR: 38.0–56.0) years], a higher proportion of cirrhosis (51.6 *vs.* 35.0), and a higher rate of comorbidity (39.0 *vs.* 12.8).

Nonetheless, the effectiveness of SARS-CoV-2 vaccines diminished over a period. The two doses of homologous ChAdOx1 vaccines were 68% effective in preventing COVID-19 at 15–30 days after administration, but no efficacy was detected at 121 days after administration^[20]. Three doses of ZF2001 vaccines in preventing COVID-19 were 75.7% effective in healthy individuals in 6 months after administration^[21]. At 6 months after the third dose of SARS-CoV-2 vaccines, the positive serological rate of nCoV NTAb was >50%^[22]. The positive rate of nCoV S-RBD in liver transplant patients was increased from 56% to 98% by the third dose of the BNT162b2 vaccine^[23]. After receiving the third dose of SARS-CoV-2 vaccine, the level of nCoV NTAb in solid tumor patients was improved by three times compared to two doses but was still lower than that in the healthy

control group^[24]. Several studies have shown the humoral immune response of patients with CLD after primary immunity with SARS-CoV-2 vaccines. However, data regarding booster immunity on the humoral immune response in patients with CLD are lacking. In this study, the positive rate of nCoV NTAb was increased by 28.08%, and the antibody level was increased by 2.77 times after booster immunity. The positive rate of nCoV S-RBD was increased by 22.17%, and the antibody level was increased by 5.22-fold after booster immunity. In conclusion, after booster immunity of SARS-CoV-2 vaccine, the humoral immune response in patients with CLD could be improved after primary immunity.

A total of 22 patients underwent antibody detection of SARS-CoV-2 vaccines after both primary and booster immunities to further confirm the dynamic change in antibodies after booster immunity. Subsequently, the positive rate of nCoV NTAb increased from 59.09% to 86.36%, and the positive rate of nCoV S-RBD increased from 68.18% to 90.91%. The median level of nCoV NTAb increased from 11.24 AU/mL to 59.14 AU/mL after booster immunity. The median level of nCoV S-RBD was increased from 27.28 AU/mL to 219.10 AU/mL. Compared to the antibody level of primary immunity, the median level of nCoV

NtAb and nCoV S-RBD was increased by 5.26- and 8.03-fold, respectively. Consistent with the literature^[25], patients with CLD improve the humoral immune response after completing booster immunity, and the antibody level of patients with autoimmune hepatitis negative for nCoV S-RBD was increased by 148-fold^[25]. Booster immunity prompted an immune response in liver transplant patients negative for nCoV S-RBD^[23]. 9/22 patients were negative for nCoV NtAb after primary immunity, while 6 cases were transformed positive after booster immunity, and the positive conversion rate of nCoV NtAb was 66.7%. A total of 7 patients were negative for nCoV S-RBD after primary immunity, while 5 cases were transformed positive after booster immunity; the positive conversion rate of nCoV S-RBD was 71.4%. The positive conversion rate among patients with primary immunity failure can be improved after booster immunity, such that patients with primary immunity failure can obtain immunity to COVID-19.

In this study, subgroup analysis was performed to compare the immune response in patients with non-cirrhosis and cirrhosis in both Primary and Booster groups. Consistent with previous studies^[5, 19], the positive rate and level of nCoV NtAb and nCoV S-RBD had no significant difference between non-cirrhosis and

cirrhosis patients in Primary. However, the positive rate of nCoV NTAb and nCoV S-RBD without cirrhosis was higher than that in patients with cirrhosis in Booster. Patients with cirrhosis have congenital and adaptive immune dysfunction^[26] and B cell phenotypic and functional defects^[27]. The number of total T lymphocytes decreases in patients with cirrhosis, while CD4+ and CD8+ T cells expressing apoptosis markers are significantly increased^[28]. These explain the unsatisfactory immune response of patients with cirrhosis after receiving SARS-CoV-2 vaccines.

In the present study, we analyzed the data of 22 patients whose antibodies were negative after primary and booster immunity, respectively. Due to the small samples, statistical analysis was not conducted. We found that patients with negative SARS-CoV-2 antibodies after primary immunity were older and had a high proportion of cirrhosis than those with positive antibodies. After booster immunity, 3 were negative for SARS-CoV-2 antibody, 1 was negative only for nCoV NTAb, and 2 were negative for both nCoV NTAb and nCoV S-RBD. First, 3 cases were cirrhotic and older. In patients with only nCoV NTAb negative, the level of nCoV S-RBD was 11.91 AU/mL. The patient was 74-years-old and had a BMI of 31.6, so the effect of SARS-CoV-2 vaccine was not optimal after booster immunity.

Previous studies reported that SARS-CoV-2 antibody level was inversely correlated with age and BMI^[5, 23, 29], suggesting that elderly with underlying diseases, such as cirrhosis and obesity, should receive booster vaccinations regularly to obtain sustained immunity against COVID.

Consistent with the results of current studies^[5, 19], most of the local and systemic adverse reactions in patients with CLD after primary immunity were mild and could be alleviated in this study. The most common local adverse effect after primary immunity was pain at the injection site, and the most common systemic adverse effect was fatigue. Reportedly, the adverse reactions of healthy individuals are mild after booster immunity^[21, 22]. In this study, we found that the adverse reactions of patients with CLD after booster immunity were mostly mild and self-limited. The most common local adverse reaction after booster immunity was pain at the injection site, and the most common systemic adverse reaction was fatigue.

The level of nCoV NTAb predicts vaccine protection^[30]. Regarding the gold standard for the detection of nCoV NTAb^[31, 32], plaque reduction neutralization test (PRNT) involves live virus, and the cell culture and low detection throughput require a high laboratory level and complex procedure. In the present study,

competitive combined chemiluminescence immunoassay (CLIA) was used, which has the characteristics of high automation and throughput^[33]. A major target of the SARS-CoV-2 vaccine is the S protein, especially the RBD region on the S protein^[34]. A strong correlation was established between nCoV NTAb and nCoV S-RBD, and it has been confirmed that the detection of nCoV SRBD antibodies is highly-sensitive and specific^[35]. Therefore, two types of antibodies, nCoV NTAb and nCoV S-RBD, were determined in this study.

Nevertheless, the present study has several limitations. This was a single-center study, and the samples were from the same region. Thus, samples from other regions should be enrolled in the future to make the research results universal. During this study, only the humoral immunity status of patients with CLD who completed SARS-CoV-2 vaccination was evaluated, and the cellular immunity status of patients with CLD who completed the SARS-CoV-2 vaccine was not evaluated, which is crucial to understand the immunogenicity of SARS-CoV-2 vaccine. During the study, only patients with CLD were included, and healthy individuals were not included as the control group, which did not allow the comparison of the differences in the immunogenicity of SARS-CoV-2 vaccine between patients with CLD and healthy

individuals. In the future, we would need to include additional specimens with populations from other areas to confirm our conclusions further.

To date, some countries have started to vaccinate high-risk groups with the fourth dose of the SARS-CoV-2 vaccine^[36]; this study provided data support for the formulation of vaccination strategies. In conclusion, patients with CLD improved the humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improved the positive rate and antibody level of patients with CLD. Finally, the positive conversion rate among patients with primary immunity failure could be improved after booster immunity.

References

- [1] World Health Organization Coronavirus (COVID-19) Dashboard [M].<https://covid19.who.int/table> Accessed October 20, 2022
- [2] McMenamin M E, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study [J]. *The Lancet Infectious Diseases*, 2022, 22(10): 1435-1443.
- [3] Li T Y, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review [J]. *World J Gastroenterol*, 2019, 25(27): 3527-3537.
- [4] Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? [J]. *World J Hepatol*, 2021, 13(5): 522-532.
- [5] Bakasis A D, Bitzogli K, Mouziouras D, et al. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases [J]. *Viruses*, 2022, 14(2).

- [6] Mathieu. E, Ritchie H, Rodés-Guirao L, et al. Our World in Data: Coronavirus (COVID-19) Vaccinations [M]. <https://ourworldindata.org/coronavirus> Accessed October 21, 2022
- [7] Lin D Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina [J]. *N Engl J Med*, 2022, 386(10): 933-941.
- [8] Tartof S Y, Slezak J M, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study [J]. *The Lancet*, 2021, 398(10309): 1407-1416.
- [9] Moreira E D, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine [J]. *N Engl J Med*, 2022, 386(20): 1910-1921.
- [10] Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J]. *The Lancet*, 2021, 398(10316): 2093-2100.
- [11] Hepatology C S o. Chinese guidelines on the management of liver cirrhosis [J]. *Journal of Clinical Hepatology*, 2019, 35(11): 2408-2425.
- [12] China N H C o t P s R o. Technical guidelines for vaccination of COVID-19 (version 1) [J]. *Chinese Journal of Clinical Infectious Diseases*, 2021, 14(02): 89-90.
- [13] Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J]. *N Engl J Med*, 2020, 383(27): 2603-2615.
- [14] Uysal E B, Gumus S, Bektore B, et al. Evaluation of antibody response after COVID-19 vaccination of healthcare workers [J]. *J Med Virol*, 2022, 94(3): 1060-1066.
- [15] Chen Y, Yin S, Tong X, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine [J]. *Clin Microbiol Infect*, 2022, 28(3): 410-418.
- [16] Ye C, Zhang S, Zhang X, et al. Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China [J]. *J Med Virol*, 2020, 92(11): 2821-2829.
- [17] Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J]. *EBioMedicine*, 2021, 74(103705).
- [18] Lontos M, Terpos E, Markellos C, et al. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors [J]. *Vaccines (Basel)*, 2021, 9(10).
- [19] Ai J, Wang J, Liu D, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study [J]. *Clin Gastroenterol Hepatol*, 2022, 20(7): 1516-1524.
- [20] Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden [J]. *The Lancet*, 2022, 399(10327): 814-823.
- [21] Dai L, Gao L, Tao L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults [J]. *N Engl J Med*, 2022, 386(22): 2097-2111.
- [22] Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials [J]. *Lancet Infectious Diseases*, 2022, 22: 483-495.

- [23] Davidov Y, Indenbaum V, Tsaraf K, et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients [J]. *J Hepatol*, 2022, 77(3): 702-709.
- [24] Shroff R T, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors [J]. *Nat Med*, 2021, 27(11): 2002-2011.
- [25] Hartl J, R  ther D F, Duengelhof P M, et al. Analysis of the humoral and cellular response after the third COVID-19 vaccination in patient with autoimmune hepatitis [J]. *Liver International*, 2022, 10.1111.
- [26] Sipeki N, Antal-Szalmas P, Lakatos P L, et al. Immune dysfunction in cirrhosis [J]. *World J Gastroenterol*, 2014, 20(10): 2564-2577.
- [27] Doi H, Iyer T K, Carpenter E, et al. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population [J]. *Hepatology*, 2012, 55(3): 709-719.
- [28] Marquez M, Fernandez-Gutierrez C, Montes-de-Oca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis [J]. *Clin Exp Immunol*, 2009, 158(2): 219-229.
- [29] Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers [J]. *The Lancet Respiratory Medicine*, 2021, 9(9): 999-1009.
- [30] Khoury D S, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [J]. *Nat Med*, 2021, 27(7): 1205-1211.
- [31] Okba N M A, Muller M A, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients [J]. *Emerg Infect Dis*, 2020, 26(7): 1478-1488.
- [32] Perera R A, Mok C K, Tsang O T, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 [J]. *Euro Surveill*, 2020, 25(16).
- [33] Muruato A E, Fontes-Garfias C R, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation [J]. *Nat Commun*, 2020, 11:4059.
- [34] Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines [J]. *Semin Immunol*, 2020, 50:101422.
- [35] Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patient [J]. *Science Immunology*, 2020, 5(48).
- [36] Magen O, Waxman J G, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting [J]. *N Engl J Med*, 2022, 386(17): 1603-1614.

Table 1 Baseline demographic and clinical characteristics

Characteristic	Primary	Booster	P-Value
N	223	114	
Age, year	55.0 (43.0-63.0)	53.0(43.8-60.0)	0.331
Gender, male	131 (58.7)	72(63.2)	0.433
Race, Han	219 (98.2)	330 (97.9)	0.731
BMI	24.7±3.6	24.8±3.5	0.921
Etiology			0.003
HBV	152(68.2)	98(86.0)	
HCV	21 (9.4)	5(4.4)	
ALD	10 (4.5)	1 (0.9)	
AIH、PBC	10 (4.5)	6 (5.3)	
others	30 (13.5)	4 (3.5)	
Presence of cirrhosis	115(51.6)	52(45.6)	0.301
Child-Pugh class			0.863
A	107 (93.0)	49 (94.2)	
B	4 (3.5)	2 (3.8)	
C	4 (3.5)	1(1.9)	
Comorbidities	87 (39.0)	39(34.2)	0.421
Hypertension	55 (24.7)	21 (18.4)	0.195
Diabetes	31 (13.9)	12 (10.5)	0.380
CAD	5 (2.2)	5 (4.4)	0.273

Asthma	4 (1.8)	0 (0.0)	0.304
Arrhythmia	1 (0.4)	1 (0.9)	0.628
Vaccine category			0.052
BBIBP-CorV	108 (48.4)	46 (40.4)	
CoronaVac	98 (43.9)	52 (45.6)	
CansinoBio	17 (7.6)	11 (9.6)	
CHO cell Vac	0 (0.0)	5 (4.4)	
Time interval	53 (31-100)	102 (45-145)	0.000
Liver function			
ALT(U/L)	24.0 (18.0-33.0)	22.0 (16.0-36.0)	0.403
AST(U/L)	23.0 (19.0-30.0)	22.0 (18.0-32.0)	0.718
ALB (g/L)	47.8(45.5-49.6)	47.6 (45.7-51.2)	0.349
TBIL(μmol/L)	16.1(13.2-21.3)	14.4 (11.1-21.7)	0.350
GGT(U/L)	25.0(17.0-47.0)	34.5 (17.8-53.3)	0.243
ALP(U/L)	75.0(63.0-93.0)	83.0 (57.5-101.5)	0.638

Data was presented as median (interquartile range), Mean \pm standard deviation, or frequencies(percentage). Vaccine category referred to the type of first dose COVID-19 vaccine. Time interval meant the time (days) between the completion of primary or booster immunity and the collection of serological samples. BMI, Body Mass Index; HBV, Hepatitis B virus; HCV, Hepatitis C virus; ALD, Alcoholic liver disease; AIH, Autoimmune hepatitis; PBC, Primary biliary cholangitis; CAD, Coronary artery disease; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ALB, Albumin; TBIL, Total bilirubin; GGT, Gamma-glutamyl transpeptidase; ALP, Alkaline phosphatase.

Table 2 The humoral immune response of COVID-19 vaccine in Primary and Booster groups among patients with chronic liver disease

	Primary	Booster	P-Value
n	223	114	
nCoV NTA_b			
Positive	133 (59.64)	100 (87.72)	<0.001
Negative	90 (40.36)	14 (12.28)	
Antibody level	11.53(8.09-20.28)	31.98(15.37-96.02)	<0.001
nCoV S-RBD			
Positive	154 (69.06)	104 (91.23)	<0.001
Negative	69 (30.94)	10 (8.77)	
Antibody level	21.60(7.59-62.95)	112.65(31.91-286.56)	<0.001

Data was presented as median (interquartile range) or frequencies(percentage). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTA_b, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

Table 3 The humoral immune response of COVID-19 vaccine in Primary and Booster groups among no cirrhosis and cirrhosis patients.

	Primary		P-Val	Booster		P-Val
	no cirrhosis	cirrhosis		no cirrhosis	cirrhosis	
n	108	115		62	52	
nCoV						
NTAb						
Positive	64(59.3)	69(60.0)	0.910	58(93.5)	42(80.8)	0.048
Negative	44(40.7)	46(40.0)		4(6.5)	10(19.2)	
Antibody level	11.19 (7.85-20.26)	11.98 (8.21-20.61)	0.930	31.41 (19.49-96.02)	32.65 (11.58-99.85)	0.651
nCoV						
S-RBD						
positive	72(66.7)	82(71.3)	0.472	61(98.4)	43(82.7)	0.009
Negative	36(33.3)	33(28.7)		1(1.6)	9(17.3)	
Antibody level	17.58 (7.11-49.59)	25.08 (8.67-69.09)	0.217	102.94 (50.38-286.91)	119.42 (17.44-287.05)	0.159

Data was presented as median (interquartile range) or frequencies(percentage). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV

NtAb, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

Table 4 The dynamic changes of antibody in 22 patients performing twice antibody tests.

	Primary	Booster	P-Value
n	22	22	
nCoV NTAbs			
Positive	13 (59.09)	19 (86.36)	0.042
Negative	9 (40.91)	3 (13.64)	
Antibody level	11.24(8.59-17.00)	59.14(20.89-128.99)	<0.001
nCoV S-RBD			
Positive	15 (68.18)	20 (90.91)	0.062
Negative	7 (31.82)	2 (9.09)	
Antibody level	27.28(7.80-56.45)	219.10(63.11-456.05)	<0.001

Data was presented as median (interquartile range) or frequencies(%). Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAbs, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.

Table 5 Demographic and clinical characteristics of nCoV NTA b positive and negative after primary immunity in 22 patients.

characteristic	Positive	Negative
N	13	9
Age,year	54.0 (49.5-67.5)	57.0 (46.5-66.0)
Gender,male	8 (61.5)	5 (55.6)
BMI	24.3 (19.7-30.4)	24.0 (22.7-28.1)
Time interval	36 (28-81)	100 (43-138)
Presence of cirrhosis	7 (53.8)	8(88.9)
Comorbidities	5(38.5)	3(33.3)

Data was presented as median (interquartile range) or frequencies(%). Time interval meant the time (days) between the completion of primary immunity and the collection of serological samples. BMI, Body Mass Index.

Table 6 Demographic and clinical characteristics of nCoV S-RBD positive and negative after primary immunity in 22 patients.

characteristic	Positive	Negative
N	15	7
Age,year	54.0(48.0-67.0)	57.0(48.0-74.0)
Gender,male	9 (60.0)	4 (57.1)
BMI	25.1 (20.2-30.5)	23.6 (22.6-25.5)
Time interval	36 (30-83)	100 (56-136)
Presence of cirrhosis	9(60.0)	6(85.7)
Comorbidities	6 (40.0)	2(28.6)

Data was presented as median (interquartile range) or frequencies(%). Time interval meant the time (days) between the completion of primary immunity and the collection of serological samples. BMI, Body Mass Index.




Figure 1 The humoral immune response of COVID-19 vaccine in Primary and Booster groups among patients with chronic liver disease

Figure A revealed the positive rate of nCoV NTAbs in Primary and Booster groups. Figure B revealed the level of nCoV NTAbs in Primary and Booster groups. Figure C revealed the positive rate of nCoV S-RBD in Primary and Booster groups. Figure D revealed the level of nCoV S-RBD in Primary and Booster groups. Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAbs, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.




Figure 2 The level of nCoV NTab and nCoV S-RBD in Primary and Booster groups among patients with no cirrhosis and cirrhosis.

Figure A showed the level of nCoV NTab and Figure B showed the level of nCoV S-RBD. nCoV NTab, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.




Figure 3 The dynamic changes of antibody in 22 patients performing twice antibody tests.

Figure A revealed the positive rate of nCoV NTAbs and nCoV S-RBD in Primary and Booster groups. Figure B revealed the level of nCoV NTAbs and nCoV S-RBD in Primary and Booster groups. Figure C revealed the dynamic change of nCoV NTAbs after primary immunity and booster immunity. Figure D revealed the dynamic change of nCoV S-RBD after Primary immunity and booster immunity. Antibody level above 10.0 AU/mL was regarded as positive, while antibody level below 10.0 AU/mL was regarded as negative. nCoV NTAbs, novel coronavirus neutralizing antibody; nCoV S-RBD, novel coronavirus spike receptor-binding domain antibody.